Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.
Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.
Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications
Les immunothérapies sont l’avenir de la rhumatologie.
Hélène Joubert
Le Quotidien du Médecin. | 2026 Mar 31. Version en ligne. URL : lequotidiendumedecin.fr. Sujets : Immunothérapie ; Rhumatologie ; Maladies auto-immunes.
Une femme guérie de trois maladies auto-immunes grâce à une immunothérapie anticancer.
Anne Prigent
Le Figaro Santé | 2026 Apr 14. Online ahead of print. Sujets : Maladies auto-immunes; Immunothérapie.












